Gsa Capital Partners LLP Chemo Centryx, Inc. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $307,809 - $678,253	-16,747 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $220,725 - $332,093	16,747 New	16,747 $286,000
Q2 2020 Aug 11, 2020	SELL	$38.58 - $65.07 $197,298 - $332,767	-5,114 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$32.73 - $50.78 $413,183 - $641,046	-12,624 Reduced 71.17%	5,114 $205,000
Q4 2019 Feb 12, 2020	BUY	$6.81 - $39.55 $120,795 - $701,537	17,738 New	17,738 $702,000
Q3 2019 Nov 12, 2019	SELL	$6.47 - $8.96 $392,224 - $543,173	-60,622 Closed	0 $0
Q2 2019 Aug 06, 2019	SELL	$8.31 - $14.85 $255,765 - $457,053	-30,778 Reduced 33.67%	60,622 $564,000
Q1 2019 May 15, 2019	SELL	$10.01 - $13.89 $164,164 - $227,796	-16,400 Reduced 15.21%	91,400 $1.27 Million
Q4 2018 Feb 12, 2019	SELL	$9.15 - $12.26 $521,550 - $698,820	-57,000 Reduced 34.59%	107,800 $1.18 Million
Q3 2018 Nov 13, 2018	BUY	$10.49 - $13.72 $1.07 Million - $1.4 Million	102,100 Added 162.84%	164,800 $2.08 Million
Q2 2018 Aug 09, 2018	BUY	$10.62 - $13.98 $665,874 - $876,546	62,700 New	62,700 $826,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.